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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
viscosupplementation is effective in reducing osteoarthritis knee pain
Study Design: Review of three randomized, double blind, placebo control trials between 20092010
Data Sources: Three randomized, double blind, placebo control trials were found via PubMed
and NCBI
Outcomes Measured: Each randomized control trial measured knee pain and/or patient
satisfaction following their intervention (placebo or hyaluronic acid) in patients with knee
osteoarthritis, which was measured via WOMAC pain scale and patient global assessment forms.
Results: All three randomized studies showed treatment with hyaluronic acid (hylan G-F 20)
were statistically significant (P<0.05) for change in pain at 14-26 weeks after injection (NNT=68 for Chevalier et al and 4 for Kul-Panza & Berker). Patient satisfaction was higher in the
experimental groups as compared to the control with conclusions of NNT between 11 and 20 for
Chevalier et al and Kul-Panza & Berker respectively. Chavelier et al found adverse events such
as arthralgias and joint effusion in <10% of their study population (NNH=39). No dichotomous
data was presented in Diacoglu et al; however an ANOVA was deemed statistically significant
(p<0.01)
Conclusions: Review of these articles concludes that the use of hyaluronic acid is beneficial in
reducing knee pain and exhibits patient satisfaction. The use of hyaluronic acid needs to be
evaluated on a case-by-case basis and should not be used in every patient with osteoarthritis,
particularly if other additional knee injuries or significant surgical history are present.
Key Words: hyaluronic acid, osteoarthritis, knee pain
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INTRODUCTION
Osteoarthritis (OA) is a joint disease characterized by degeneration of cartilage with
damage to the collagen proteoglycan matrix.1 This paper evaluates three double blind, placebo
controlled, randomized controlled trials (RCTs) comparing the severity of knee pain and patient
satisfaction in those with osteoarthritis who received viscosupplementation (Hylan G-F 20)
versus placebo.
OA is the most common form of arthritis and is in the top 5 leading causes of disability in
the US.2 The number of adults with osteoarthritis is 51.8 million, 22.1% of the United States
population.3 In 2009, it was estimated that health care costs for total knee replacements was
$28.5 billion.2 Furthermore, the cost per patient for OA is ~$5,700 each year.2 There are 11.3
million visits to physician offices, hospital outpatient facilities and emergency departments every
year for OA, as reported in 2010.3 The above statistics confirm the importance of providing pain
relief to patients with OA in efforts to decrease the number of health care visits and expensive
surgeries, in turn, decreasing health care costs.
The exact etiology of osteoarthritis is unknown, but it may be idiopathic or secondary to
trauma and other medical conditions, such as diabetes, acromegaly, lyme disease, obesity, and
peripheral neuropathies.1,2 OA results in non-inflammatory pain with common sites being the
hips, knees, hands, spine, particularly sparing the elbows, wrists and ankles.1,2 The best way to
evaluate the severity of OA is radiographs.1,2 The radiographic pathology and hallmarks are
osteophytes, eburnation, joint space narrowing and sclerosis.2
First line treatment for OA is acetaminophen with additional treatments including
NSAIDS, and COX specific NSAIDs with physical therapy.1 Patients also benefit from
unloading braces for the knee to relieve pressure on the joint space suffering significant cartilage
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breakdown. Other measures are the use of capsaicin cream, chondroitin and
viscosupplementation.4 Surgical treatment options include arthroscopy with the definitive
treatment being a total joint replacement.1
Total joint replacement requires general anesthesia, immense rehabilitation, risk of
infection and other post op complications. The use of viscosupplementation injection directly
into the knee joint has shown to be effective in reducing pain symptoms of osteoarthritis and
prolong the need for knee replacement. 4-6 Viscosupplementation allows for lubrication of the
knee joint by replacing the degraded hyaluronic acid in synovial fluid .4-6 Viscosupplementation
allows the joint to move easily, relieving the pain from the joint grinding bone on bone from
cartilage degeneration.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not
viscosupplementation is effective in reducing osteoarthritis knee pain.
METHODS
Middle to older adult men and women with knee osteoarthritis were included in all three
studies. The intervention was viscosupplementaiton (hylan G-F 20) with a visually matched
placebo comparison (0.9% saline). The studies measured knee pain and/or patient satisfaction
following their intervention, using WOMAC pain scale and patient global assessment forms. All
studies were randomized, double blind, placebo control trials.
All articles are published in peer-reviewed journals between 2009 and 2010 and
published in English. Key words used during research via Pubmed and NCBI were
“viscosupplementation AND osteoarthritis”; “hylan AND patient satisfaction”. The articles
chosen were based on relevance to the clinical question and presented outcomes as POEMs

Antonoplos, hyaluronic acid and OA 3
(patient oriented evidence that matters). Inclusion criteria were RCTs published between 20092010 and exclusions were patients who had secondary arthropathies, trauma, surgeries or recent
corticosteroid injections. Statistics reported were relative benefit increase (RBI), absolute benefit
increase (ABI), numbers needed to treat (NNT), relative risk increase (RRI), absolute risk
increase (ARI), numbers needed to harm (NNH), p-value. Table 1 represents the demographics
and characteristics of the included studies.
Table 1: Demographics and Characteristics of Included Studies
Study
Type
#pts Age
Inclusion
External
Criteria
Criteria
Chevalier Double 253 >40 y/o
-Patients >40 -secondary OA
et al
blind
y/o with
in target knee
(2010)4
RCT
primary
-clinically
osteoarthritis apparent
knee pain
effusion in
criteria
affected knee
-OA with
-grade IV OA
medial and
-OA of
or lateral
contralateral
tibiofemoral knee
compartment -systemic CS
-grade II or
in any joint
III OA
within 3 mo
before
screening
KulDouble 48
Treatment
Men and
No exclusion
Panza &
blind
group age=
women with criteria
Berker
RCT
59.5 ± 8.8
diagnoses of reported
5
(2010)
years
U/L or B/L
-grades 1-4
Placebo
OA
group age=
62.8 ± 7.8
years
Diracoglu Double
et al
blind
6
(2009)
RCT

63

Treatment
group
age=59.4 ±
9.9 year
Placebo

-pts with B/L
knee
osteoarthritis
-stage II or
III
-minimum 50

-pts with co
arthropathies, trauma or
previous
surgeries x1 yr
-pts who

W/
D
21

Intervention

3

3 inj of 2 mL
of 1.5%
hydraluronate
sodium intraarticular
injection to
knee with
osteoarthritis
(U/L or B/L)

3

3 intrarticular
Hylan G-F 20
(Synvisc ®)
injections, 1
week apart

Single 6mL
intra-articular
injection of
hylan G-F 20
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group age=
56.2 ± 7.2
years

points from
VAS scale of
100mm
during
motion

received HA
injections past
6 mo from
screening
-pregnancy

OUTCOMES MEASURED
Outcomes measured included pain level and patient satisfaction following the
intervention. Chevalier et al4 used the WOMAC pain scale A1-pain while walking for evaluation
of treatment at week 18 and week 26 following injection. This was measured on a scale of none,
mild, moderate, severe, extreme4. Additionally, Chevalier et al4 used a patient global assessment
and patient pain assessment forms to determine patient satisfaction following treatment. These
forms evaluated satisfaction on a scale of feeling “very well, well, fair, poor, very poor”.4
Chevalier et al4 provided adverse events as dichotomous data, reporting the number of
individuals in both experimental and control groups who experienced arthralgias, joint effusion,
arthritis, arthropathies, or injection site pain.
Kul-Panza & Berker5 used a WOMAC scale evaluating pain on walking, climbing stairs,
pain at night and on sitting, lying, and standing at 14 weeks after injection. Patient satisfaction 14
weeks after injection was determined via patient questionnaire by feeling “ worse, no change,
minimal improvement, moderate improvement, very effective”.5 Lastly, Diracoglu et al6 did not
present dichotomous data, but ran an ANOVA and recorded a p-value for all WOMAC
parameters as well as resting and activity VAS pain.
RESULTS
Two of the randomized control trials reported dichotomous data, whereas, Diracoglu et
al6 reported data as continuous. All three studies used hylan GF-20 in the experimental group and
saline 0.9% in the control group. Chevalier et al4 used one injection of hylan GF-20 for
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treatment, whereas Diracoglu et al6 used three injections separated by one week and patients in
Kul-Panza5 received three injections in one week. Kul-Panza & Berker5 reported that their study
population came from patients who were attending the Physical Medicine and Rehabilitation
Output Clinic at Marmara University School of Medicine in Istanbul and presented with knee
pain and a diagnosis of OA. Chevalier et al4 and Diracoglu et al6 did not report the setting of the
patient population, but noted that their patients required a diagnoses of OA. The number of
patients who withdrew from the study were 21 in Chevalier et al4 and 3 patients in both KulPanza &Berker5 and Diracoglu et al6, from a total patient population of 253, 48, and 63
respectively (Table 1).
Chevalier et al4 noted that they lost 9 patients from their treatment group and 12 patients
from the placebo group due to failure to keep on study schedule. Additionally, 1 patient was
randomly assigned to the treatment group but received the placebo by error and therefore was
then counted in the placebo group for analysis.4 Diracoglu et al6 reported that 1 patient from the
placebo group was lost in follow-up due to not benefitting from the treatment, while 2 patients
from the treatment group were lost in follow-up due to difficulty attending the clinic for
treatment injections. The 3 patients lost from Kul-Panza5 were due to failure to attend follow-up
visits. Furthermore, the inclusion and exclusion criteria for the patients in the study are noted in
Table 1.
Table 2 demonstrates the efficacy of hylauronic acid on pain. Chevalier et al4 analyzed
the WOMAC scales from patients at 18 and 26 weeks after hylan G-F 20 injections. The NNT
were calculated from the WOMAC criteria, “pain on walking”.4 At 18 weeks, 71% of patients
from the hylan G-F 20 group (treatment) and 53% of patients from the control group were
responders.4 Responders were interpreted as those patients reporting a decrease in pain level
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while walking. This was calculated into a NNT of 6 (Table 2). At 26 weeks, 64% of the patients
in the experimental group and 50% in the control group were responders, leading to a NNT of
8.4 The difference between the control and treatment groups was deemed significant by a p-value
of 0.003 at 18 weeks and 0.028 at 26 weeks.4 This data concluded that 18 weeks would need to
pass following the treatment of 6 individuals for 1 more patient to see results.4 Furthermore, 26
weeks would need to pass following the treatment of 8 individuals for 1 more patient to see
results.4
Kul-Panza & Berker5 recorded WOMAC score of walking pain at 14 weeks after
injections. The percentage of improvement in pain while walking was significantly higher in the
experimental group (35.2%) compared to the control group (9.1). This was calculated into a
NNT of 4, meaning that 4 patients would need to be treated with viscosupplementation for 1
more patient have a decrease in pain when compared to placebo (Table 2). The treatment at 14
weeks on walking pain was statistically significant in the treatment group over the placebo as
noted by a p value 0.01 in ANOVA.5 No dichotomous data was reported from Diacoglu et al6 and
no continuous data was able to be converted to dichotomous. An ANOVA was run and VAS
pain values as well as all WOMAC parameters except stiffness were significantly lower in the
treatment group, as noted by a p value of <0.01 (Table 2).6
Table 2. Efficacy of hyaluronic acid in the treatment of knee osteoarthritis
Study
Relative benefit
Absolute benefit Numbers needed
increase (RBI)
increase (ABI)
to treat (NNT)
Chevalier et al
34%
18%
6
4
(2010) -at 18
weeks
Chevalier et al
28%
14%
8
(2010) 4- at 26
weeks
Kul-Panza &
2.86%
26.1%
4
Berker
(2010)5

P-value
0.003
0.028
0.01
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Diracoglu et al
(2009)6

n/a

n/a

n/a

<0.01

Two of the randomized control trials reported dichotomous data on patient satisfaction
following their treatment intervention.4,5 Chevalier et al4 reported patient global assessment on
the basis of feeling very well, well, fair, poor, very poor. To determine treatment success, the
categories “very well, well and fair” were used to calculate NNT. Based on this determination of
success, 74.2% of patients in the experimental group and 64.4% of patients in the control group
reported the intervention successful.4 The NNT for patient satisfaction was then calculated to be
11 (Table 3). Kul-Panza & Berker5 reported patient satisfaction as either no change from
baseline, minimal improvement, moderate improvement, or very effective. Included in the
calculation for NNT were the categories “minimal improvement, moderate improvement, and
very effective”. This correlated to a reported 87% patient satisfaction in the treatment group
compared to an 82% in the control group.5 The NNT was calculated to be 20 (Table 3). Of these
results, it is concluded that for 1 more patient to find the treatment successful, between 11 and 20
patients would need to be treated.
Table 3. Efficacy of hylauronic acid on patient satisfaction of knee OA improvement
Study
Relative benefit
Absolute benefit
Numbers needed to
increase (RBI)
increase (ABI)
treat (NNT)
Chevalier et al
15.2%
9.8%
11
(2010) 4 at 26 weeks
Kul-Panza & Berker 6%
5%
20
(2010)5- at 14weeks
Only one randomized trial provided dichotomous data to calculate NNH based on adverse
events of the treatment. Chevalier et al4 demonstrated that 5.7% of the patients in the
experimental group experienced some adverse events while 3.1% in the control group. This
correlates to a NNH of 39, concluding that for every 39 people treated with hylauronic acid, 1
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more person will experience an adverse event when compared to control (Table 4). The most
common adverse events were arthralgia, joint effusion, and arthritis with a maximum of 2
patients in each category reporting such events.4 Adverse events were not reported in Diracoglu
et al.6 Only 1 patient in the treatment group and control group of Kul-Panza & Berker5 reported
an adverse, with this event being knee instability.
Table 4. Adverse events of hyaluronic acid 4
Adverse reactions
Relative risk Absolute risk
increase
increase (ARI)
(RRI)
Any treatment and/or
83.8%
2.6%
procedure related target
knee adverse events4

Numbers
needed to
harm (NNH)
39

P-value
0.366

DISCUSSION
The above results suggest a benefit to the use of hyaluronic acid in patients with
osteoarthritis. The NNT for pain from all three studies are between 4-8 suggesting that you need
to treat an average of 6 patients in order for 1 more patient to see benefits (Table 2). The NNT
for patient satisfaction are fairly higher, ranging from 11-20, suggesting that around 15 people
need to be treated in order to have 1 more patient satisfied with the outcome (Table 3). The NNH
for Chevalier et al4 was 39, ensuring that a larger number of people can be treated before an
adverse event occurs (Table 4). Even so, the adverse events reported were not serious and
consisted of temporary knee issues. 4-6
There may be a variety of reasons why the NNT for patient satisfaction is higher. Many
patients want to see immediate results from treatments, especially when pain is involved.
Hyaluronic acid takes an average of 5 weeks for patients to see improvements in their OA.7,8 The
product provides relief of symptoms for on average, 6 months.7,8 Even though these global
assessment forms were given to the patient at least 3 months following the injections, patients
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may have too high of expectations on joint improvements. Hyaluronic acid is not a definitive
treatment for OA, and many physicians offering this treatment are prolonging the need for
invasive options, such as arthroscopy and total joint replacement.1,7
Hyaluronic acid is only FDA approved for knee osteoarthritis, even though some
physicians use the injection off label in hips and/or shoulders without insurance coverage to the
patient.7 Hyaluronic acid comes as brand names Synvisc ® , Orthovisc ®, Hyalgan ® .7 Medicare
and most insurance companies cover the costs of hyaluronic acid products; however if the
product is not covered through insurance or it is injected off label, the product can cost up to
$661 for 5 vials7,8,9 There are no black box warnings for these products but should not be used in
patients with joint or skin infections, venous stasis or leg edema.8 Particularly for Synvisc ® ,
allergy to feathers, eggs or poultry are a contraindication due to the use of chicken combs in the
product.8
There are some limitations in the studies that should be discussed. There was a failure to
analyze all drop outs, leading to a potential bias in the studies.4-6 A limitation in the efficacy of
hylauronic acid is noted in Kul-Panza & Berker5 because the study only lasted 3 months,
therefore no long term effects could be evaluated. Additionally, there was no difference between
the two group outcomes except at week 14 evaluation of walking pain.5 There is a possible
placebo effect in all the studies, where the improvement in symptoms may be psychological
more so than the effect of the actual composition of the injections.4-6 Kul-Panza & Berker5 as
well as Diracoglu et al6 had relatively small sample sizes of 48 and 63 respectively, compared to
Chevalier et al4 sample of 253. Lastly, Chevalier et al4 and Kul-Panza & Berker allowed the
patients to use other analgesics and physical therapy exercise during the course of the study,
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while Diracoglu et al6 did not allow any exercise routine nor the use of analgesics. These
discrepancies may have skewed the results provided in the articles.
CONCLUSION
The results of this review suggest that hyaluronic acid is safe and effective for the use of
knee osteoarthritis. Even though a NNT could not be calculated for Diracoglu et al6, an ANOVA
was conducted and therefore a p-value was provided for interpretation of statistical significance.
The articles showed little adverse events with an NNH of 39 from Chevalier et al4. Statistics
further show that adverse events occur in <2% of patients who receive hyaluronic injections,
those events being joint pain and effusion and edema.8 Further research is needed to evaluate the
efficacy of hyaluronic acid in all joints, with the hope to make the product FDA approved for
shoulder and hip OA. Further studies should also evaluate patient’s pain and satisfaction at
multiple time frames, from 1 week after injection to greater than 6 months after injection, in
efforts demonstrate bell curve in efficacy of the injections overtime.
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